Found 177 matching trials
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
PHASE3This is a multicenter, randomized controlled, phase III clinical trial. The...
Location
Sun Yat-sen University Cancer Center
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
N/AManagements for refractory proficient mismatch repair (pMMR) or microsatell...
Location
Hunan Cancer hospital
Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma
PHASE2The IO/TKI regimens which combines Immune checkpoint inhibitors (IO) with T...
Location
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
PHASE1This is a Phase 1, open-label, dose escalation study in patients with advan...
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
PHASE2Research purposes: the research design in the late more than 2 lines TNBC p...
Location
Tianjin Cancer Hospital Airport Hospital
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
PHASE1Chemotherapeutic agents exert significant immunomodulatory effects by influ...
Location
the First Affiliated Hospital of Zhengzhou University
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
PHASE2This is a prospective, Bayesian adaptive, phase II clinical trial designed ...
Location
Cancer Center of Guangzhou Medical University
Phase โ
/โ
ก Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
PHASE1This is an open-label, single-arm, dose-escalation, and dose-expansion clin...
Location
Cancer Hospital Chinese Academy of Medical Sciences
JS001+IMP4297 in Patients With Advanced Cancer
PHASE1This is a Phase I/Ib open-label, multicenter study to evaluate the safety, ...
Location
Multiple Locations
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
N/AThis study is conducted to evaluate the efficacy, prognosis, adverse effect...
Location
The Second Affiliated Hospital of Fujian Medical University